Terms: = Ovarian cancer AND MUTYH, MYH, 4595, ENSG00000132781, hMYH, MGC4416, MYHbeta AND Treatment
11 results:
1. Secondary (additional) findings from the 100,000 Genomes Project: Disease manifestation, health care outcomes, and costs of disclosure.
Nolan J; Buchanan J; Taylor J; Almeida J; Bedenham T; Blair E; Broadgate S; Butler S; Cazeaux A; Craft J; Cranston T; Crawford G; Forrest J; Gabriel J; George E; Gillen D; Haeger A; Hastings Ward J; Hawkes L; Hodgkiss C; Hoffman J; Jones A; Karpe F; Kasperaviciute D; Kovacs E; Leigh S; Limb E; Lloyd-Jani A; Lopez J; Lucassen A; McFarlane C; O'Rourke AW; Pond E; Sherman C; Stewart H; Thomas E; Thomas S; Thomas T; Thomson K; Wakelin H; Walker S; Watson M; Williams E; Ormondroyd E
Genet Med; 2024 Mar; 26(3):101051. PubMed ID: 38131308
[TBL] [Abstract] [Full Text] [Related]
2. Uncommon variants detected via hereditary cancer panel and suggestions for genetic counseling.
Özdemir Z; Çevik E; Öksüzoğlu ÖBÇ; Doğan M; Ateş Ö; Esin E; Bilgetekin İ; Demirci U; Köseoğlu Ç; Topal A; Karadurmuş N; Erdem HB; Bahsi T
Mutat Res; 2023; 827():111831. PubMed ID: 37453313
[TBL] [Abstract] [Full Text] [Related]
3. DNA Repair Pathway in ovarian cancer Patients Treated with HIPEC.
Flasarova D; Urban K; Strouhal O; Klos D; Lemstrova R; Dvorak P; Soucek P; Mohelnikova-Duchonova B
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240218
[TBL] [Abstract] [Full Text] [Related]
4. Hereditary breast cancer and fertility preservation outcomes.
Arab S; Tulandi T; Buckett W
J Assist Reprod Genet; 2022 May; 39(5):1163-1168. PubMed ID: 35403930
[TBL] [Abstract] [Full Text] [Related]
5. Forty-eight-year-old female mutyh carrier presenting with five concurrent primary cancers.
Arroyave A; Nodit L; Clegg D; Russ A
Cancer Rep (Hoboken); 2022 Feb; 5(2):e1455. PubMed ID: 34173730
[TBL] [Abstract] [Full Text] [Related]
6. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast cancer or ovarian cancer, 2012-2019.
Kurian AW; Ward KC; Abrahamse P; Bondarenko I; Hamilton AS; Deapen D; Morrow M; Berek JS; Hofer TP; Katz SJ
J Clin Oncol; 2021 May; 39(15):1631-1640. PubMed ID: 33560870
[TBL] [Abstract] [Full Text] [Related]
7. Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage.
Giovannini S; Weller MC; Repmann S; Moch H; Jiricny J
Nucleic Acids Res; 2019 Sep; 47(17):9132-9143. PubMed ID: 31329989
[TBL] [Abstract] [Full Text] [Related]
8. Inherited DNA repair gene mutations detected by tumor next generation sequencing in urinary tract cancers.
Gupta S; Greenberg S; Grimmett J; Gaston D; Agarwal N; Lowrance W; Schiffman J; Kohlmann W
Fam Cancer; 2017 Oct; 16(4):545-550. PubMed ID: 28315974
[TBL] [Abstract] [Full Text] [Related]
9. Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer.
Khrunin AV; Khokhrin DV; Moisseev AA; Gorbunova VA; Limborska SA
Pharmacogenomics; 2014 Feb; 15(3):329-37. PubMed ID: 24533712
[TBL] [Abstract] [Full Text] [Related]
10. Dry eye syndrome in aromatase inhibitor users.
Turaka K; Nottage JM; Hammersmith KM; Nagra PK; Rapuano CJ
Clin Exp Ophthalmol; 2013 Apr; 41(3):239-43. PubMed ID: 22957932
[TBL] [Abstract] [Full Text] [Related]
11. [Hereditary colorectal cancer].
Park JG; Kim IJ
Korean J Gastroenterol; 2005 Feb; 45(2):78-87. PubMed ID: 15725711
[TBL] [Abstract] [Full Text] [Related]
